ArticleBiomolecules2026
Longitudinal Follow-Up of microRNA Expression During Hepatitis E Virus Infection in Immunocompromised Hosts.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is a zoonotic cause of acute viral hepatitis that can become chronic in immunocompromised patients. Recently, host microRNAs (miRNAs) miR-122-5p, miR-125b-5p, miR-99a-5p, and miR-192-5p have been associated with acute HEV infection and with chronic HEV infection. Yet, the expression levels of miRNAs during the early phase of HEV infection remained unexplored. In this context, we aimed to identify changes in miRNA profiles occurring between the diagnosis of HEV infection and HEV cure in immunocompromised patients and in a pig model. We retrospectively included 9 immunocompromised patients with HEV infection (5 chronic and 4 resolutive) and 10 immunocompromised pigs (6 HEV-infected and 4 controls). RNAseq was retrospectively performed on pig samples. MiRNA expression was quantified by qPCR on pig and human samples.: Small RNA sequencing and targeted qPCR analyses revealed a pronounced, stage-dependent remodeling of miRNA expression during HEV infection. In patients, viral clearance was associated with early upregulation of miR-99a-5p, miR-122-5p, miR-125b-5p, and miR-194-5p, whereas progression to chronic infection was characterized by sustained downregulation of miR-23a-3p, miR-27a-3p, miR-106a-5p, miR-221-3p, and miR-223-3p. Likewise, a correlation was observed between the dysregulation of miR-181a-5p, miR-425-5p, and let-7b-5p with viral load (HEV RNA), while miR-27a-3p and miR-106a-5p were associated with ALT levels. In pigs, miR-122-5p was upregulated 10 weeks p.i., while 10 miRNAs (miR-16, miR-20a-5p, miR-23a-3p, miR-27a, miR-29a-3p, miR-140-5p, miR-181a, miR-191, miR-423-5p, and miR-99a-5p) were downregulated 11 weeks p.i. MiR-23a-3p, miR-27a, miR-99a-5p, miR-181a, and miR-425-5p were associated with HEV infection in both humans and pigs. Persistent HEV infection in immunocompromised patients and in a pig model showed partial overlap in miRNA responses. Our findings identified circulating miRNAs as stage-specific molecular markers of HEV infection in immunocompromised hosts. MiRNAs could contribute to early stratification of high-risk patients, improving outcomes for vulnerable patients facing this emerging viral disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.